Compare CLOV & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLOV | EVO |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | CLOV | EVO |
|---|---|---|
| Price | $2.24 | $3.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.35 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 6.2M | 68.7K |
| Earning Date | 02-26-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,773,564,000.00 | $887,396,457.00 |
| Revenue This Year | $41.68 | N/A |
| Revenue Next Year | $43.92 | $8.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.15 | N/A |
| 52 Week Low | $2.12 | $2.84 |
| 52 Week High | $4.80 | $4.80 |
| Indicator | CLOV | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 36.71 | 56.52 |
| Support Level | $2.45 | $3.53 |
| Resistance Level | $2.73 | $3.81 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 5.22 | 54.17 |
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.